The role of Akkermansia muciniphila, one of the most abundant microorganisms of the intestinal
microbiota, has been studied extensively in metabolic diseases, such as obesity and diabetes. It
is considered a next-generation probiotic microorganism. Although its mechanism of action has
not been fully elucidated, accumulating evidence indicates the important role of A. muciniphila
in brain functions via the gut-brain axis and its potential as a therapeutic target in various neuropsychiatric disorders. However, only a limited number of studies, particularly clinical studies, have directly assessed the therapeutic effects of A. muciniphila interventions in these disorders. This is
the first review to discuss the comprehensive mechanism of A. muciniphila in the gut-brain axis
via the protection of the intestinal mucosal barrier and modulation of the immune system and
metabolites, such as short-chain fatty acids, amino acids, and amino acid derivatives.
Additionally, the role of A. muciniphila and its therapeutic potential in various neuropsychiatric
disorders, including Alzheimer’s disease and cognitive deficit, amyotrophic lateral sclerosis,
Parkinson’s disease, and multiple sclerosis, have been discussed. The review suggests the potential role of A. muciniphila in healthy brain functions. CLICK TO REVIEW